Sage Therapeutics, Inc. (NASDAQ:SAGE) had its target price cut by research analysts at J P Morgan Chase & Co from $99.00 to $85.00 in a report released on Tuesday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price objective would indicate a potential upside of 20.79% from the stock’s current price.

A number of other brokerages have also issued reports on SAGE. Leerink Swann reaffirmed an “outperform” rating and issued a $97.00 price target (up from $90.00) on shares of Sage Therapeutics in a research note on Tuesday, June 20th. ValuEngine raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Stifel Nicolaus started coverage on Sage Therapeutics in a research note on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price target on shares of Sage Therapeutics in a research note on Tuesday, June 13th. Finally, Canaccord Genuity set a $110.00 price target on Sage Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 5th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Sage Therapeutics has an average rating of “Buy” and an average target price of $84.08.

Shares of Sage Therapeutics (NASDAQ SAGE) opened at 70.37 on Tuesday. Sage Therapeutics has a one year low of $38.30 and a one year high of $90.80. The stock’s 50 day moving average price is $82.79 and its 200 day moving average price is $74.97. The stock’s market capitalization is $2.63 billion.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.63) by ($0.25). During the same period in the previous year, the business earned ($1.08) earnings per share. Equities research analysts predict that Sage Therapeutics will post ($7.38) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “J P Morgan Chase & Co Lowers Sage Therapeutics, Inc. (SAGE) Price Target to $85.00” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/12/sage-therapeutics-inc-sage-pt-lowered-to-13-70-at-j-p-morgan-chase-co.html.

A number of institutional investors have recently made changes to their positions in SAGE. Teachers Advisors LLC lifted its position in Sage Therapeutics by 15.0% during the fourth quarter. Teachers Advisors LLC now owns 49,296 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 6,419 shares in the last quarter. Bank of Montreal Can lifted its position in Sage Therapeutics by 7,004.1% during the first quarter. Bank of Montreal Can now owns 12,006 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 11,837 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in Sage Therapeutics during the first quarter worth approximately $256,000. Russell Investments Group Ltd. lifted its position in Sage Therapeutics by 82.1% during the first quarter. Russell Investments Group Ltd. now owns 19,679 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 8,872 shares in the last quarter. Finally, Swiss National Bank lifted its position in Sage Therapeutics by 3.2% during the first quarter. Swiss National Bank now owns 52,100 shares of the biopharmaceutical company’s stock worth $3,703,000 after buying an additional 1,600 shares in the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.